The Delta Variant is 55% more virulent than the Alpha Variant. Evidence shows that it can evade antibody-based treatments and that it can potentially increase the risk of reinfection in people who have recovered from COVID caused by another strain.
Take a look at the infographic for more insight on the impact of the Delta Variant.
Our unique approach can help your company navigate the complexities of launching a drug, biologic or medical device into multiple markets. The first step? Connecting. Simply fill out our form and a representative will follow-up shortly.
1.877.787.0177
510.732.0177
22320 Foothill Blvd. Suite 330, Hayward CA 94541
